Summary Congress 2014

Summary Congress 2016

Eventos relacionados

Visit Counter

This Week
Last Week
This Month
Last Month

Photos of the 2016 UPD Congress with the treatment of Heberprot-P




Congress 2018

International Congress Workshop on Practical Application of human recombinant Epidermal Growth Factor (hrEGF) in Patients with Diabetic Foot Ulcer

Date: December, 2018
To be held at Melia Habana Hotel, Cuba

Main topics

  • Main elements of the healing mechanism in diabetic patients.
  • Role of human recombinant Epidermal Growth Factor (hrEGF) in wound healing.
  • Development and main achievements of Heberprot-P therapy.
  • Practical Procedures backed up by the Cuban Health Ministry for the comprehensive care of diabetic foot ulcers.
  • Diabetic foot ulcer classification used in Cuba.
  • Practical procedures in the treatment of neuropathic diabetic foot ulcers.
  • Practical procedures in the treatment of ischemic diabetic foot ulcers.
  • Most frequent reported adverse events using Heberprot-P.
  • Practical experiences in the treatment of very complex diabetic foot ulcers.

International Congress: Controlling diabetes and its more severe complications

Date: December 2018.
To be held at: Memories Varadero Hotel, Varadero, Matanzas, Cuba

Endorse this conclave:

  • Cuban Society of Diabetes.
  • Cuban Society of Endocrinology.
  • Cuban Society of Angiology and Vascular Surgery.
  • Center for Genetic Engineering and Biotechnology.
  • HeberBiotec SA.


Main topics

  • Diabetes prevention.
  • Diabetes as metabolic .
  • Links between obesity and diabetes.
  • Diabetes type 1 and 2. Global medical updates in early detection, metabolic control and treatments.
  • Gestational Diabetes.
  • Retinopathy, nephropathy and neuropathy produced by diabetes.
  • Incretine system and cardiovascular protection.
  • Diabetes control through insulin. State of the art in insulinization.
  • Molecular biology of wound healing mechanisms.
  • Failure of healing mechanisms in diabetic patients.
  • Role of different growth factors in regulating wound healing mechanisms.
  • Diabetic foot ulcer as a severe diabetes complication.
  • Could be considered the local infiltration of human recombinant growth factor (hrEGF) (Heberprot-P) the first and unique replacement therapy in the treatment of diabetic foot ulcers?
  • Practical procedures in the treatment of infected diabetic foot ulcer.
  • Peripheral arterial disease.
  • Revascularization procedures.
  • Neuropathic and ischemic diabetic foot ulcer patients, main differences and similarities among them.
  • Charcot foot.
  • Main achievement and challenges in the state of the art of diabetic foot ulcer treatments.
  • Practical medical experiences in the use of human recombinant epidermal growth factor in the treatment of very complex diabetic foot ulcers.
  • Implementation of health programs to control diabetes.
  • Active surveillance for early detection of diabetic foot ulcers.
  • Role of primary, secondary and tertiary health care levels in the implementation of comprehensive care programs for diabetic foot ulcer patients.
  • Comprehensive care program to guarantee safe pregnancy in diabetic women.
  • New development in the control of diabetes.
  • Post marketing pharmaco-vigilance of Heberprot-P in the Cuban health system.
  • Biosafety record of the use of human recombinant epidermal growth factor in diabetic foot ulcer patients.